Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 6/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28031026 | 1.00 | SERPINE1 (0.57) | SERPINE1PTPN1PTPN2PTPN11ESR1 | |
| Water SCHEMBL23067557 | 0.99 | SERPINE1 (0.56) | SERPINE1PTPN1PTPN2PTPN11ESR1 | |
| SCHEMBL29935518 | 0.93 | SERPINE1 (0.50) | SERPINE1PTPN1PTPN2PTPN11ESR1 | |
| SCHEMBL5665190 | 0.90 | SERPINE1 (0.47) | SERPINE1PTPN1PTPN2PTPN11ESR1 | |
| SCHEMBL9646034 | 0.89 | SERPINE1 (0.46) | SERPINE1PTPN1PTPN2PTPN11ESR1 | |
| SCHEMBL5908258 | 0.89 | SERPINE1 (0.46) | SERPINE1PTPN1PTPN2PTPN11ESR1 | |
| SCHEMBL5666281 | 0.89 | SERPINE1 (0.46) | SERPINE1PTPN1PTPN2PTPN11ESR1 | |
| SCHEMBL5665855 | 0.88 | SERPINE1 (0.45) | SERPINE1PTPN1PTPN2PTPN11ESR1 | |
| SCHEMBL20530411 | 0.87 | SERPINE1 (0.57) | SERPINE1PTPN1PTPN2PTPN11ESR1 | |
| SCHEMBL28064168 | 0.87 | SERPINE1 (0.57) | SERPINE1PTPN1PTPN2PTPN11ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 863 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122017088-A | UPLC-based construction method of characteristic spectrum of xipayi Gum fixing liquid and method for measuring content of characteristic components of UPLC-based construction method | 新奇康药业股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4696341-A1 | MEDICAL DEVICE AND SYSTEM, AND PREPARATION METHOD | Shanghai MicroPort Medical (Group) Co., Ltd. (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4108265-B1 | FUNCTIONALIZED BIOLOGICAL MATRIX MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | VENUS MEDTECH HANGZHOU INC (CN) | 2025-09-03 | — | — | EP | claimed |
| WO-2025130396-A1 | TRMT61A INHIBITOR PGG IN THE TREATMENT OF COLORECTAL CANCER | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2025-06-26 | — | — | WO | claimed |
| CN-116999568-B | Space-time controllable drug delivery system for targeting tumor extracellular matrix and application | 安徽中医药大学 | 2025-05-27 | — | — | CN | claimed |
| WO-2025096874-A1 | COMPOUNDS AND METHODS FOR USING GALLOYLATED POLYPHENOLS TO TREAT DISEASES MEDIATED BY THIOL ISOMERASES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-05-08 | — | — | WO | claimed |
| CN-119915929-A | Radix paeoniae rubra quality marker screening method based on anticoagulation spectrum effect relationship | 内蒙古医科大学 | 2025-05-02 | — | — | CN | claimed |
| US-20250134853-A1 | COMPOUNDS AND METHODS FOR USING GALLOYLATED POLYPHENOLS TO TREAT DISEASES MEDIATED BY THIOL ISOMERASES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2025-05-01 | — | — | US | claimed |
| CN-119678840-A | Multi-element aggregation and prepotency breeding method for paeonia lactiflora seeds | 亳州职业技术学院 | 2025-03-25 | — | — | CN | claimed |
| WO-2025052177-A2 | NOVEL COMPOSITION AND METHODS OF TREATING A NEURODEGENERATIVE DISEASE | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2025-03-13 | — | — | WO | claimed |
| WO-2004009094-A1 | METHODS AND COMPOSITIONS FOR TREATING DIABETES MELLITIS | OHIO UNIVERSITY (US) | 2004-01-29 | — | — | WO | claimed |
| US-20030161903-A1 | Carbohydrate Aborption Inhibitor and Method for Manufacturing the Same | ORYZA OIL & FAT CHEMICAL CO., LTD. (JP) | 2003-08-28 | — | — | US | claimed |
| EP-1232169-A1 | GALLOTANNINS AND ELLAGITANNINS AS REGULATORS OF CYTOKINE RELEASE | THE PENN STATE RESEARCH FOUNDATION (US) | 2002-08-21 | — | — | EP | claimed |
| WO-2001036436-A1 | GALLOTANNINS AND ELLAGITANNINS AS REGULATORS OF CYTOKINE RELEASE | THE PENN STATE RESEARCH FOUNDATION (US) | 2001-05-25 | — | — | WO | claimed |
| WO-1998042350-A1 | CHOLESTEROL LOWERING PHARMACEUTICAL COMPOSITION | CHEIL JEDANG CORPORATION (KR) | 1998-10-01 | — | — | WO | claimed |
| US-5159069-A | Viricide, enzyme inhibitor | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1992-10-27 | — | — | US | claimed |
| EP-0374888-A2 | Sulfated tannins and theirs salts | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-06-27 | — | — | EP | claimed |
| US-4741915-A | PENTAGALLOYL GLUCOSE | NESTEC S.A. (CH) | 1988-05-03 | — | — | US | claimed |
| EP-0131176-B1 | ANTI-OXYGEN PROTECTION OF NUTRITIOUS AND COSMETIC PRODUCTS | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 1987-12-16 | — | — | EP | claimed |
| EP-0131176-A1 | Anti-oxygen protection of nutritious and cosmetic products | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 1985-01-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250134853-A1 | COMPOUNDS AND METHODS FOR USING GALLOYLATED POLYPHENOLS TO TREAT DISEASES MEDIATED BY THIOL ISOMERASES | GGT1, SPR, PON1 | SERPINE1 20/4885PTPN1 984/4885PTPN2 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.